regn1908

mAbexperimental

Clinical trial activity

5 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
4
Phase 3
2
Phase 4
0

Earliest trial started Aug 1, 2013 (NCT01922661)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • feld1INHIBITOR

    feld1 inhibitor

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • regn1908

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06602726Phase 3Oct 15, 2024Regeneron
NCT04981717Phase 3Jul 30, 2021Regeneron
NCT03838731Phase 2Feb 12, 2019Regeneron
NCT02127801Phase 1/Phase 2 (Phase 2)Oct 1, 2014Regeneron
NCT01922661Phase 1Aug 1, 2013Regeneron
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RegeneronFor profit5532013
1 organizations
Page 1 / 1